On 15 June, Amylyx Pharmaceuticals, a clinical-stage pharmaceutical company developing a novel therapeutic for Amyotrophic Lateral Sclerosis, Alzheimer’s disease (AD) and other neurodegenerative diseases, announced that it has completed the enrolment of its Phase II trial evaluating AMX0035 in people with AD. AMX0035 is a combination of existing compounds designed to prevent neuroinflammation and nerve cell death. The PEGASUS Phase II trial is a 24-week randomised, double-blind, multi-site and placebo-controlled study evaluating the safety and tolerability of AMX0035 in people with late mild cognitive impairment or early dementia due to AD. The company announced that it has recruited 96 research participants and expects to share topline results of the PEGASUS trial in early 2021.
Amylyx Pharmaceuticals announces completion of enrolment of its PEGASUS Phase II trial for Alzheimer’s disease
15/06/2020
